Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gain Therapeutics, Inc.

2.36
-0.1109-4.49%
Volume:112.49K
Turnover:262.23K
Market Cap:62.58M
PE:-2.18
High:2.44
Open:2.44
Low:2.25
Close:2.47
Loading ...

Company Profile

Company Name:
Gain Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
31
Office Location:
4800 Montgomery Lane,Suite 220,Bethesda,Maryland,United States
Zip Code:
20814
Fax:
- -
Introduction:
Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Directors

Name
Position
Eric Richman
Chief Executive Officer, Director
Khalid Islam
Founder and Chairman
Claude Nicaise
Director
Dov Goldstein
Director
Gwen Melincoff
Director
Hans Peter Hasler
Director
Jeffrey Riley
Director

Shareholders

Name
Position
Eric Richman
Chief Executive Officer, Director
Salvatore Calabrese
Chief Financial Officer
Manolo Bellotto
President, General Manager